Sono-Tek Corp. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Sono-Tek Corporation for the period ended August 31, 2009. Sono-Tek develops and manufactures ultrasonic atomizing nozzles and coating systems for electronics, medical devices (specifically stent coating), and industrial applications (WideTrack systems). The company is a smaller reporting company incorporated in New York.
Key Financial Metrics
| Metric | Six Months Ended Aug 31, 2009 | Three Months Ended Aug 31, 2009 |
|---|---|---|
| Net Sales | $3,148,612 | $1,683,883 |
| Gross Profit | $1,564,522 (50% Margin) | $907,141 (54% Margin) |
| Operating Income (Loss) | $(129,910) | $40,651 |
| Net Income (Loss) | $(128,881) | $40,546 |
| Cash from Operations | $166,511 | Filing text does not provide a clear value for the three-month period |
| Cash and Equivalents (End of Period) | $1,504,203 | |
| Total Debt (Current + Long Term) | $281,333 ($250k Line of Credit + $31,333 Notes) | |
| Working Capital | $2,873,608 |
Material Changes vs. Prior Period
- Revenue: Six-month sales decreased 2% ($77,000) compared to the prior year, while three-month sales increased 5% ($79,000) due to higher sales of fluxer units, nozzles, and stent coaters.
- Profitability: The company reported a net loss of $129,000 for the six months ended August 31, 2009, a significant improvement from the $308,000 loss in the same period in 2008. The three-month period turned profitable with $41,000 in net income.
- Margins: Gross profit margin improved to 54% in the three-month period (up from 47% in 2008) due to a more profitable product mix and reduced labor costs.
- Expenses: Operating expenses decreased significantly. Research and development costs dropped $78,000 (six-month view) due to reduced engineering personnel. General and administrative costs fell $118,000 due to voluntary officer salary reductions and lower stock-based compensation.
- Cash Flow: Operating cash flow turned positive at $167,000 for the six-month period, reversing a $943,000 usage in the prior year, driven by a $102,000 decrease in accounts receivable.
Outlook, Risks, and Management Commentary
- Guidance: Management expects a profitable third quarter following the profitable second quarter, citing an increasing backlog of anticipated sales. They anticipate a 15% sales increase in Q3 similar to the Q2 growth over Q1.
- Strategic Focus: The company is diversifying away from the cyclical US electronics market (which has declined due to offshore production) toward international sales (now ~55% of revenue), medical devices, and clean energy (solar/fuel cells).
- Liquidity: The company maintains a $500,000 revolving line of credit with $250,000 currently utilized. The current ratio is 3.71 to 1.
- Risks: Key risks include the cyclical nature of the electronics industry, dependence on international markets, and the need for continued capital investment in new product development (WideTrack, medical, clean energy) with no guarantee of success.
- Unusual Items: The company recorded a gain on the sale of equipment of $53,309 during the six-month period.
Investor Verification Checklist
- Verify the sustainability of the 54% gross margin in the third quarter, as it was driven by a specific product mix shift.
- Confirm the status of the "increasing backlog" cited by management as the basis for Q3 profitability expectations.
- Monitor the $250,000 line of credit utilization and the requirement to pay it down for 30 days annually to avoid conversion to a term note.
- Review the impact of the voluntary officer salary reductions on future retention and operational capacity.
- Assess the progress of the WideTrack and medical device markets, which are critical to offsetting the decline in US electronics sales.